Abstract

The United States faces critical vulnerabilities in its supply chain infrastructure, characterized by geographic concentration of manufacturing in select regions and limited domestic production capacity across multiple sectors. This research examines the structural fragilities that have emerged from decades of globalization, cost optimization, and just-in-time manufacturing practices. The analysis reveals that 72% of API facilities supplying the U.S. market are overseas, with significant dependencies on foreign production. An estimated 80% of APIs and 40% of finished pharmaceuticals consumed in the US are manufactured abroad, primarily in China and India. The study explores how economic efficiency priorities have inadvertently created systemic vulnerabilities that became evident during the COVID-19 pandemic and recent geopolitical tensions. Key findings demonstrate critical dependencies in pharmaceuticals, semiconductors, rare earth materials, and essential manufacturing. The research analyzes trade-offs between cost efficiency and supply chain resilience, examining how geographic concentration creates single points of failure across critical industries. Strategic recommendations include building domestic manufacturing capacity, supply chain diversification, and regional resilience frameworks while maintaining economic competitiveness in the global marketplace.